Article Contents ::
- 1 The Brand Name BONIMET Has Generic Salt :: IBANDRONIC
- 2 BONIMET Is From Company Intas Priced :: Rs. 2480
- 3 BONIMET have IBANDRONIC is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name BONIMET Has Generic Salt :: IBANDRONIC
BONIMET Is From Company Intas Priced :: Rs. 2480
BONIMET have IBANDRONIC is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| IBANDRONIC | INJ | Rs. 2480 | VIAL |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / VIAL |
| BONIMET | Intas | 6MG | VIAL | Rs. 2480 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Intas :: BONIMET | IBANDRONIC | #N/A | #N/A |
Indications for Drugs ::
Post-menopausal osteoporosis, Hypercalcaemia of malignancy, Breast cancer and bone metastases
Drug Dose ::
Adult: PO Prevention and treatment of postmenopausal osteoporosis As ibandronic acid: 150 mg once mthly on the same date each mth or 2.5 mg/day. Prevention of skeletal events in breast cancer and bone metastases As ibandronic acid: 50 mg/day. IV Hypercalcaemia of malignancy As ibandronic acid: 2-4 mg as a single dose. Max: 6 mg/dose. Prevention and treatment of postmenopausal osteoporosis As ibandronic acid: 3 mg once 3 mthly. Prevention of skeletal events in breast cancer and bone metastases As ibandronic acid: 6 mg 3-4 wkly.
Contraindication ::
Severe renal impairment, uncorrected hypocalcaemia, acute upper GI inflammation, inability to stand or sit upright for at least 60 min (oral).
Drug Precautions ::
History of bone/joint/muscle pain; dysphagia, oesophageal disease, gastritis, duodenitis, ulcers. Risk factors for osteonecrosis of the jaw. Pregnancy and lactation.
Drug Side Effects ::
Fever; influenza-like syndrome; electrolyte disturbances; GI disturbances; musculoskeletal pain; headache; rash, allergic dermatitis; anaemia; decreased alkaline phosphatase; hypercholesterolaemia; UTI; local reactions (parenteral); renal impairment (parenteral).
Pregnancy category ::
3
Drug Mode of Action ::
Ibandronic acid is a potent bone resorption inhibitor, which acts on osteoclasts or on osteoclast precursors. It increases bone mineral density by reducing the rate of bone resorption.
Drug Interactions ::
Impaired absorption with aluminium, calcium, iron, magnesium compounds. Increased risk of GI or renal adverse effects with NSAIDs. Additive hypocalcaemic effects with aminoglycosides.
